| # | Drug | Count |
|---|---|---|
| 0 | PANITUMUMAB | 861 |
| 1 | BEVACIZUMAB | 597 |
| 2 | FLUOROURACIL | 593 |
| 3 | FLUOROURACIL CREAM, 0.5% | 593 |
| 4 | OXALIPLATIN | 549 |
| 5 | FRUQUINTINIB | 396 |
| 6 | REGORAFENIB | 321 |
| 7 | CAPECITABINE | 172 |
| 8 | LEUCOVORIN CALCIUM | 130 |
| 9 | CETUXIMAB | 129 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | FRUQUINTINIB | 396 | 0.1005 |
| 1 | PANITUMUMAB | 861 | 0.0535 |
| 2 | REGORAFENIB | 321 | 0.0276 |
| 3 | FLOXURIDINE | 2 | 0.0116 |
| 4 | SOTORASIB | 36 | 0.0104 |
| 5 | ESTRONE | 1 | 0.0093 |
| 6 | FLUOROURACIL CREAM, 0.5% | 593 | 0.0076 |
| 7 | FLUOROURACIL | 593 | 0.0075 |
| 8 | OXALIPLATIN | 549 | 0.0072 |
| 9 | TRIFLURIDINE AND TIPIRACIL | 77 | 0.0071 |
| # | Drug class | Count |
|---|---|---|
| 0 | Epidermal Growth Factor Receptor Antagonist [EPC] | 923 |
| 1 | Nucleoside Metabolic Inhibitor [EPC] | 733 |
| 2 | Vascular Endothelial Growth Factor Inhibitor [EPC] | 643 |
| 3 | Platinum-based Drug [EPC] | 553 |
| 4 | Nucleoside Analog Antiviral [EPC] | 110 |
| 5 | Corticosteroid [EPC] | 65 |
| 6 | Nonsteroidal Anti-inflammatory Drug [EPC] | 61 |
| 7 | Factor Xa Inhibitor [EPC] | 54 |
| 8 | Benzodiazepine [EPC] | 50 |
| 9 | Opioid Agonist [EPC] | 37 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Epidermal Growth Factor Receptor Antagonist [EPC] | 923 | 0.0195 |
| 1 | Vascular Endothelial Growth Factor Inhibitor [EPC] | 643 | 0.0035 |
| 2 | Nucleoside Metabolic Inhibitor [EPC] | 733 | 0.0027 |
| 3 | Platinum-based Drug [EPC] | 553 | 0.0020 |
| 4 | Interleukin-5 Antagonist [EPC] | 1 | 0.0015 |
| 5 | Nucleoside Analog Antiviral [EPC] | 110 | 0.0013 |
| 6 | Vascular Endothelial Growth Factor Receptor 2 Antagonist [EPC] | 6 | 0.0009 |
| 7 | Lymphocyte Growth Factor [EPC] | 1 | 0.0008 |
| 8 | Provitamin D2 Compound [EPC] | 17 | 0.0006 |
| 9 | Guanylate Cyclase-C Agonist [EPC] | 1 | 0.0005 |